{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T17:30:40Z","timestamp":1775410240584,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.pharma.2008.11.003","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T04:21:22Z","timestamp":1236226882000},"page":"104-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["La maladie d\u2019Alzheimer et les pharmaciens en contact avec le public"],"prefix":"10.1016","volume":"67","author":[{"given":"C.","family":"Dreux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2008.11.003_bib1","unstructured":"Maladie d\u2019Alzheimer\u00a0: enjeux scientifiques, m\u00e9dicaux et soci\u00e9taux. Paris\u00a0: Ed. Lavoisier \u2013 Collection Expertise collective; 2007."},{"key":"10.1016\/j.pharma.2008.11.003_bib2","first-page":"19","article-title":"Maladie d\u2019Alzheimer nouveaux traitements et vaccins \u00e0 l\u2019\u00e9tude","volume":"132","author":"Dubois","year":"2008","journal-title":"AIM"},{"key":"10.1016\/j.pharma.2008.11.003_bib3","unstructured":"La Pr\u00e9vention en question(s). Journ\u00e9e scientifique du groupe de concertation entre Acad\u00e9mies des sciences de la Vie et de la Sant\u00e9. Paris\u00a0: Lavoisier;2009."},{"key":"10.1016\/j.pharma.2008.11.003_bib4","unstructured":"Rapport J. Menard pour un plan national concernant la maladie d\u2019Alzheimer et les maladies apparent\u00e9es. www.premier-ministre-gouv.fr\/IMG\/pdf\/plan2008-2012.pdf. (Consult\u00e9 en avril 2007)."},{"key":"10.1016\/j.pharma.2008.11.003_bib5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0755-4982(06)74810-2","article-title":"Facteurs de risque de la maladie d\u2019Alzheimer\u00a0: vers une pr\u00e9vention\u00a0?","volume":"35","author":"Vogel","year":"2006","journal-title":"Presse Med"},{"key":"10.1016\/j.pharma.2008.11.003_bib6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0755-4982(05)84049-7","volume":"34","author":"Vogel","year":"2005","journal-title":"Presse Med."},{"key":"10.1016\/j.pharma.2008.11.003_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MOL.0b013e32813aeabf","article-title":"Cholesterol metabolism, apolipoprot\u00e9ine E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease","volume":"18","author":"Hirsch-Reinshagen","year":"2007","journal-title":"Curr Opin in Lipidology"},{"key":"10.1016\/j.pharma.2008.11.003_bib8","unstructured":"Association France Alzheimer. Livre vert de la maladie d\u2019Alzheimer et maladies apparent\u00e9es. 2006."},{"key":"10.1016\/j.pharma.2008.11.003_bib9","first-page":"207","article-title":"Maladie d\u2019Alzheimer\u00a0: quels traitements\u00a0?","volume":"19","author":"Geny","year":"2005","journal-title":"Rev Prat Med Gen"},{"key":"10.1016\/j.pharma.2008.11.003_bib10","unstructured":"La r\u00e9\u00e9valuation des m\u00e9dicaments anti-Alzheimer. Haute Autorit\u00e9 de sant\u00e9. 2007."},{"key":"10.1016\/j.pharma.2008.11.003_bib11","unstructured":"Allain H, Zekri O, Javaudin L, Michel BF. La maladie d\u2019Alzheimer. Fiche technique CESSPF, juillet 1998."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450908001624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450908001624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:26:47Z","timestamp":1757719607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450908001624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0003450908001624"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2008.11.003","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La maladie d\u2019Alzheimer et les pharmaciens en contact avec le public","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2008.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}